Representative Jonathan L. Jackson (D-Illinois) recently bought shares of Doximity, Inc. NASDAQ: DOCS. In a filing disclosed on September 23rd, the Representative disclosed that they had bought between $15,001 and $50,000 in Doximity stock on August 25th. The trade occurred in the Representative's "MORGAN STANLEY TRUST ACCOUNT" account.
Representative Jonathan L. Jackson also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Fomento Economico Mexicano NYSE: FMX on 7/17/2025.
- Purchased $1,001 - $15,000 in shares of ARM NASDAQ: ARM on 7/17/2025.
Doximity Trading Up 0.6%
DOCS stock opened at $74.36 on Thursday. The stock has a market capitalization of $13.93 billion, a PE ratio of 74.36, a price-to-earnings-growth ratio of 4.10 and a beta of 1.37. Doximity, Inc. has a 12-month low of $40.87 and a 12-month high of $85.21. The stock's 50 day simple moving average is $65.46 and its 200 day simple moving average is $60.17.
Doximity (NASDAQ:DOCS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.05. Doximity had a return on equity of 21.75% and a net margin of 36.60%.Doximity's revenue was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.28 EPS. Doximity has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. On average, research analysts predict that Doximity, Inc. will post 0.99 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms have recently commented on DOCS. KeyCorp upped their price objective on Doximity from $65.00 to $70.00 and gave the stock an "overweight" rating in a research note on Monday, July 14th. BTIG Research upgraded Doximity from a "neutral" rating to a "buy" rating and set a $80.00 price objective for the company in a research note on Monday, June 2nd. Truist Financial increased their price target on Doximity from $52.00 to $61.00 and gave the stock a "hold" rating in a research note on Thursday, July 17th. Evercore ISI upgraded Doximity from an "in-line" rating to an "outperform" rating and increased their price target for the stock from $50.00 to $70.00 in a research note on Wednesday, July 9th. Finally, Robert W. Baird increased their price target on Doximity from $75.00 to $80.00 and gave the stock an "outperform" rating in a research note on Thursday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and eleven have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $67.42.
Check Out Our Latest Stock Report on Doximity
Institutional Trading of Doximity
Large investors have recently added to or reduced their stakes in the company. Hantz Financial Services Inc. boosted its position in shares of Doximity by 148.9% during the 2nd quarter. Hantz Financial Services Inc. now owns 453 shares of the company's stock valued at $28,000 after acquiring an additional 271 shares during the last quarter. VSM Wealth Advisory LLC bought a new position in Doximity during the first quarter valued at $29,000. Allworth Financial LP grew its stake in shares of Doximity by 104.0% in the 1st quarter. Allworth Financial LP now owns 563 shares of the company's stock worth $32,000 after buying an additional 287 shares in the last quarter. National Bank of Canada FI purchased a new position in shares of Doximity in the 1st quarter worth $33,000. Finally, Spire Wealth Management increased its holdings in shares of Doximity by 73.2% in the 1st quarter. Spire Wealth Management now owns 615 shares of the company's stock worth $36,000 after buying an additional 260 shares during the last quarter. Institutional investors own 87.19% of the company's stock.
Insider Transactions at Doximity
In other news, Director Regina M. Benjamin sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, July 11th. The stock was sold at an average price of $60.04, for a total value of $300,200.00. Following the completion of the sale, the director directly owned 16,618 shares of the company's stock, valued at $997,744.72. This trade represents a 23.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kira Scherer Wampler sold 2,000 shares of the firm's stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $57.09, for a total value of $114,180.00. Following the completion of the sale, the director directly owned 16,618 shares of the company's stock, valued at $948,721.62. The trade was a 10.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,000 shares of company stock valued at $1,081,880. 31.30% of the stock is owned by insiders.
About Representative Jackson
Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois' 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.
Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois' 1st Congressional District. He declared candidacy for the 2026 election.
Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson's career experience includes working as an investment analyst and an entrepreneur.
Doximity Company Profile
(
Get Free Report)
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Doximity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Doximity wasn't on the list.
While Doximity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.